IBI310

IBI310 is an investigational agent whose form is not stated in the registry developed by Innovent Biopharmaceutical Technology (Hangzhou). Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 1 mg/kg intravenous infusion, administered on Day 1 of each 6-week treatment cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07490262 (A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment), in hepatocellular carcinoma. The largest, NCT07490262, plans to enrol 680 participants with primary completion expected 2027-12-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.